Rogers (ROG) Tops Q3 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Rogers Corporation Reports Results for the 2016 Third Quarter
November 2, 2016 4:23 PM EDTNet sales of $165.3 million, up 3.1% Gross margin of 37.5%, up 30 basis points Net income of $16.1 million, up 28.1% Adjusted EBITDA of $34.1 million, 20.6% of net sales
ROGERS, Conn.--(BUSINESS WIRE)-- Rogers Corporation (NYSE: ROG) today announced financial results for the 2016 third... More
Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual Meeting
November 2, 2016 1:00 AM EDT15 oral presentations from 17 abstracts across six autoimmune conditions First presentation of Actemra data from GiACTA - the largest ever clinical trial in people with giant cell arteritis (GCA), a condition for which there has been no approved therapy in more than 50 years New data from two studies investigating cardiovascular outcomes for people with rheumatoid arthritis (RA) treated with Actemra
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),... More
